Aims The main purpose of this paper is to describe the relationship between serum concentrations of glibenclamide and its main metabolites and the effects on blood glucose levels, the clinically most relevant parameter to assess in diabetes. Methods Serum concentrations and blood glucose lowering effects (expressed as percent blood glucose reduction vs placebo) of glibenclamide (Gb) and its active metabolites, 4-trans-hydroxy-(M1) and 3-cis-hydroxy-glibenclamide (M2), were analysed in eight healthy subjects participating in a placebo-controlled, randomized, single-blind crossover study, using intravenous administration of each compound as well as oral administration of Gb. Results Plots of % blood glucose reduction vs log serum concentration demonstrated counter-clockwise hysteresis for parent drug and its metabolites. An effect compartment was linked to appropriate pharmacokinetic models and pharmacokinetic and pharmacodynamic modelling was used to fit the pharmacokinetics of Gb by both routes and the metabolites for each individual. Based on the individual concentration-time profiles a PK/PD-model was applied to all effect data simultaneously. An increase in the steady-state serum concentration when the effect is 50% of maximal, CE ss50, , was found in the sequence M1 (23 ng ml −1 ), M2
profiles but differ from Gb in clearance and volume of Introduction distribution [8] .
It is uncertain how the hypoglycaemic effect of sulphonylGlibenclamide (Gb) is a commonly used second generation sulphonylurea drug. Gb is metabolized by the liver and ureas varies with drug concentration [10] . The current study compared the concentration-effect relations of Gb, M1 and is eliminated as hydroxylated derivatives, 4-trans-hydroxy-(M1) and 3-cis-hydroxy-glibenclamide (M2) [1] [2] [3] [4] [5] [6] [7] . The M2 by modelling of pharmacokinetics and pharmacodynamics. The nonlinear mixed-effects model population program basal pharmacokinetics and urinary excretion pattern of these metabolites in man have been studied both after NONMEM [11] was used for the analysis. Thorough reviews of PK/PD-modelling and population pharmacointravenous administration of each metabolite per se, and after intravenous and oral administration of Gb [8] .
kinetics and pharmacodynamics are given in [12] [13] [14] and [15] [16] [17] , respectively. Independent of the route of administration of Gb one third of the administered dose was excreted as metabolites ( proportions, M1/M2=4) in urine within 10 h postdose Methods [8] . Recently, we showed that both M1 and M2 possess pronounced hypoglycaemic activity in man [9] . Subsequent Protocol studies showed that M1 and M2 have similar pharmacokinetic Table 1 shows characteristics of subjects and individual fasting blood glucose and insulin levels for each test. The Table 1 Characteristics of subjects and individual fasting blood glucose and serum insulin levels for each test. been previously reported [8, 9] . Only a brief summary will where: E, percent effect (t) is the percent effect at time (t), determined from the glucose levels at corresponding times be given herein. Informed written consent was obtained from each subject, and the study protocol was approved by during placebo ( placebo(t)) and treatment (treatment (t) periods). The equation defines the effect at every time the Medical Faculty Ethics Committee at Lund University, Lund, Sweden. Eight healthy Caucasian subjects (four of during placebo treatment as 0 percent, and for blood glucose the maximum possible effect (reduction) as 100 percent each sex) participated in the placebo-controlled, randomized, single-blind crossover study with five single-dose tests, 3 [20] [21] . For each test, each subject was evaluated by plotting the corresponding effect-concentration data pairs months apart; placebo intravenously, 3.5 mg doses of M1, M2, Gb intravenously and, in addition, a 3.5 mg tablet of between 0 and 5 h, and different basic pharmacodynamic models, log-linear, E max , and sigmoid E max models were Gb (DaonilA, Hoechst GmbH, Frankfurt, Germany) were administered in the fasting state. Standardised breakfast and tried and fitted to the data [22] [23] [24] . Data pairs were collected after distribution equilibrium lunch were eaten 0.5 and 5.5 h postdose. The meals had energy contents of 1,800 kJ (430 kcal) and
Fasting blood glucose (mmol l
(1-5 h for i.v. data and 2-5 h for oral data) was obtained between the central and peripheral compartments; i.e. 3,150 kJ (750 kcal), respectively. Apart from the meals, no food or liquid intake was allowed. Venous blood samples for monoexponential portion of the descending serum concentration-time curve. For experiments not performed at steadyanalyses of serum drug concentrations and blood glucose levels were drawn at regular intervals between 0 and 10 h state, the problem with counterclockwise hysteresis can be reduced, but not eliminated, by collecting the effect- Linked pharmacokinetic ( PK) and pharmacodynamic ( PD) measured by h.p.l.c. with a detection limit of 1 ng ml −1 modelling [18] , and serum and urine concentrations of M1 and M2 by
The theory behind this modelling technique was described essentially the same method, with a detection limit of in 1979 [26] and has been tested and extended [27, 28] . The 5 ng ml −1 . Metabolite concentrations in serum from the approach has been used in several studies [29] [30] [31] [32] . This tests giving Gb were not analysed. The coefficients of technique allows fitting of the serum drug concentration variation (between-day) for the assays of the three different and the effect data from non-equilibrium phases, i.e. initial sulphonylurea compounds varied between 2.5-9.8% [8] .
distribution phases after single-dose administration. The Blood glucose was assayed by a glucose oxidase method.
model has an effect site connected to a PK model. The Serum insulin concentrations were analysed by a specific drug is assumed to enter and leave the effect compartment enzyme-linked immunosorbent method [19] .
according to first-order kinetics, described by the two rate constants, k 1E and k E0.
Data analyses
To examine the time course of effects after placebo and Pharmacokinetic and pharmacodynamic analysis drug administration, plots of effect (raw data) vs time were Nonlinear mixed-effects modelling were used to characterize made, and, in order to fit data to a pharmacodynamic the pharmacokinetics and pharmacodynamics in the actual model, the effects were also plotted vs drug serum population. This modelling approach is appropriate for concentrations at the time of each effect measurement.
analysis of all subjects simultaneoulsy, taking the interindividBeforehand, effect raw data were transformed to percent ual variability into account [15] . simultaneously with a bi-exponential intravenous model and After giving initial estimates for each test, the curvea two-compartment oral model with first-order input, firstfitting was performed and the parameters were adjusted by order output and a lag time. Those models described the the NONMEM iterations to provide the best fit to the data best, and were used in later model development.
observed concentration-time and effect-time data. Weighting Estimates of k 10 , k 12 , k 21 , initial dilution volume (V 1 ), k 13 , with both an additional and a proportional weighting term k 31 , F, absorption rate constant (k a ) and lag time (t lag ) were was used. Comparison between models were based mainly sought. Following the administration of Gb, no serum on visual examination of the residual scatterplots, and measurements of M1 or M2 were made, yet knowledge of comparison of the minimum objective function values. The those profiles are necessary to properly account for the objective function computed by NONMEM is equal to contribution of these metabolites to the effect. Prediction minus twice the log likelihood [15, 16] . A stepwise approach of these profiles were based on the following assumptions:
was used to determine which parameters should be included (i) the fraction of Gb forming M1 (or M2) is equal to the in the 'final' optimal model that has the best fit (lowest-2 fraction of the dose excreted into the urine in the form of log likelihood). Parameter estimates of k E0 , E max , CE ss50 and M1 (or M2), (ii) the CL of Gb is constant over time, c for M1, M2 and Gb were sought. The half-life (iii) the disposition characteristics of M1 (M2) as determined determinating time for drug loss from the effect site, k E0-HL , from the intravenous administration of M1 (M2) apply also was calculated as (ln 2)/k E0 . Effect data after 5 h were not when the metabolite is formed from Gb. used since little effect on blood glucose levels vs placebo As a PD model for each metabolite, a reparametrised could be discerned after lunch. version of the ordinary sigmoid E max model was used to relate the intensity of effect, E, to the amount or concentration of metabolite (M1 or M2) in the hypothetical Statistical analysis effect compartment.
All data are shown as means±s. Plots of individual percent effect data vs serum concentration c is the sigmoidicity factor, which affects the sigmoid shape data exposed a time dependent concentration-effect relationof the curve [28, 31] . For combined drug action of Gb, M1
ship (counterclockwise hysteresis), which is shown for a and M2, we used a standard model for the competitive representative subject (number 1) (Figure 1a and b) . Oral interaction of three agonists [35] . It was written as: administration of Gb delayed the effect more than intravenous Gb. From urine data it was concluded that the E Gb+M1+M2 =E max metabolites appeared in serum after Gb administration between 0.5-1 h and that t max of both metabolites were
A plot of pooled percent effect data from all subjects vs where corresponding serum concentrations indicated a sigmoidal relationship. The mean percent effect data from the X Gb =CE 
and M2 (P=0.06). The resulting parameters after linear
Gb and the concentration producing 50% effect was significantly lower for both metabolites than for Gb regression analysis were summarised together with the concentrations estimated to produce 20% effect (EC 20 ) and (P<0.05). Corresponding estimated E max -values were 40%, 27% and 56% (Table 4 ). The elimination rate constant for Gb also EC 50 (Table 2) .
Individual plots showing observed and predicted values of from the effect site (k E0 ) increased and corresponding halflives (3.9 h, 1.4 h and 0.44 h) decreased in the order M1, serum concentrations of Gb after intravenous and oral administration of Gb are shown in Figure 3 . The resulting M2 and Gb (P<0.05). The half-life and time for drug loss from the effect site was almost nine (M1) and more than population pharmacokinetic parameters are shown in Table 3 . The 'final' linked PK/PD-model that had the best three times (M2) longer than that of Gb. fit assumed no baseline and also the same value of c in all subjects. Figure 4 shows individual plots of observed and Discussion predicted percent effects in two representative subjects (no. 2 and 7) for each test. The resulting population pharmacoThis study re-affirms that both major metabolites of glibenclamide possess hypoglycaemic activities in man after dynamic parameters of the eight subjects are shown in Table 4 .
intravenous administration [9] , and despite single-dose test and lack of steady-state data assessed the effect response CE ss50 -values increased in the sequence M1, M2 and log serum concentration (ngml in the concentration range level 0-500 ng ml −1 (0-1000 nmol l −1 ) by means of linked pharmacokinetic and pharmacodynamic modelling. The demonstrable hysteresis after intravenous adminis- the metabolites contribute to the observed effect on the
ordinate without contributing to concentration on the than the parent drug at lower concentrations. These results metabolites compared with the parent drug may be an explanation to the higher activity of metabolites. There are are in contrast to a previous claim that M1 is about 6.5 times less potent than Gb, following intraperitoneal adminispublished data indicating that Gb is more protein-bound in blood than M1 and M2 [1, 36] . tration of different doses of Gb and M1 in six rats [6] . A possible explanation apart from species difference, could be Administration of Gb appeared to generate at least three bioactive compounds; Gb itself with a rapid effect onset and that the animal study concerned dose-response while the current one investigated concentration-effect relationships. a short duration (k E0-HL , 0.44 h), M2 with an intermediate effect duration (k E0-HL , 1.4 h) and M1 with a slower onset Another possible explanation could be that the animal study used 20 times higher dose per kg bodyweight.
of effect and longer duration (k E0-HL , 3.9 h). The prolonged effect duration of the metabolites can be explained in terms In a non-crossover, single-dose placebo-controlled study at four dosage levels of oral glibenclamide (1.25-5.0 mg ), in of the linked PK/PD model. As the response-time curve is dependent on the slowest rate constant describing the five groups of eight subjects each, serum concentrations were measured by a radioimmunoassay which did not separate concentration in the effect site, as the k E0 values for M1 (0.178 h −1 ) and M2 (0.479 h −1 ) were smaller than their metabolites from glibenclamide [3] . The correlation with fasting serum glucose was weak. In fact, similar drug levels corresponding alpha and beta disposition constants [8] , and as the k E0 values were smaller than their corresponding k 21 could be associated with different degrees of glucose lowering, depending upon dose and time after dosing [3] . The findings rate constants, the amount of drug in the effect site cannot be directly proportional to the amount of drug in the central would fit with a counterclockwise hysteresis effect after oral administration. The authors also defined a minimum effective compartment or the amount of drug in the peripheral compartment [8, 26, 27, 32] . Also, as k E0 is the rate-limiting glibenclamide/metabolite level at 30-50 ng ml −1 . In the 1.25 dosage group they had a significant decrease in glucose levels step in the effect site, the metabolites (especially M1) will remain longer in the effect compartment than in serum. down to the 6 ng ml −1 level [3] . These data agree with the assumption that Gb and especially its metabolites are active at The long Gb half-life [37], the lag time effect, delayed absorption in some patients and bioactive metabolites with low concentrations, as suggested by the EC 20 and CE ss50 -values seen in the current study. A higher free fraction of the different effect durations all add to explain why once-daily metabolites may have higher activity at low concentrations and may have a longer effect duration than the parent drug per se. This should be clinically relevant.
dosage is sufficient in most patients. Significant prolongation in the elimination half-life [38] [39] [40] and an increased volume This study was supported in parts by grants from The Swedish Academy of Pharmaceutical Sciences (Gunnar of distribution of Gb has also been observed during chronic dosing [40] . In addition, a recent study indicates that the Hylténs Memory Fund) and Apoteksbolaget AB (The
